Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27376756 | 0.97 | AR (0.61) | ARALDH1A1HPGDCYP19A1TRPV4 | |
| SCHEMBL8543199 | 0.91 | AR (0.62) | ARALDH1A1CYP19A1TRPV4MRGPRX4 | |
| SCHEMBL13890483 | 0.86 | AR (0.56) | ARCYP19A1TRPV4MRGPRX4SLC22A12 | |
| SCHEMBL4171343 | 0.84 | AR (0.59) | ARALDH1A1HPGDTRPV4SLC22A12 | |
| SCHEMBL4174837 | 0.83 | AR (0.58) | ARALDH1A1CYP19A1MRGPRX4SLC22A12 | |
| SCHEMBL4188869 | 0.83 | AR (0.67) | ARALDH1A1CYP19A1TRPV4MRGPRX4 | |
| SCHEMBL7073821 | 0.83 | AR (0.55) | ARALDH1A1CYP19A1TRPV4MRGPRX4 | |
| SCHEMBL9747026 | 0.83 | ALDH1A1 (0.65) | ARALDH1A1HPGDCYP19A1LTA4H | |
| SCHEMBL523446 | 0.83 | ALDH1A1 (0.65) | ARALDH1A1HPGDCYP19A1LTA4H | |
| SCHEMBL9745473 | 0.83 | ALDH1A1 (0.65) | ARALDH1A1HPGDCYP19A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | claimed |
| EP-1781280-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018723-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-23 | — | — | WO | claimed |
| US-20250339437-A1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| CN-113307811-B | Tetrahydropyranyl amino-pyrrolopyrimidinones and methods of use thereof | 艾科尔公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4134369-A1 | SOLID FORMS OF TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE COMPOUNDS | ArQule, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3882250-B1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE FOR USE IN TREATING BTK-MEDIATED DISORDERS | ARQULE INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3882250-B1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE FOR USE IN TREATING BTK-MEDIATED DISORDERS | ARQULE INC (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-3882250-A1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE FOR USE IN TREATING BTK-MEDIATED DISORDERS | ArQule, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3882250-A1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE FOR USE IN TREATING BTK-MEDIATED DISORDERS | ArQule, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1781280-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018723-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-0648752-B1 | TRIAZOLE DERIVATIVE, INSECTICIDAL/ACARICIDAL AGENT, AND PROCESS FOR PRODUCING THE SAME | KUMIAI CHEMICAL INDUSTRY CO (JP) | 1999-10-06 | — | — | EP | disclosed |
| US-5700824-A | Triazole derivatives, insecticide, acaricide and methods thereof | KUMIAI CHEMICAL INDUSTRIAL CO. LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| US-5616594-A | Triazole derivatives, insecticide, acaricide and methods thereof | IHARA CHEMICAL INDUSTRY CO. LTD. (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0648752-A1 | TRIAZOLE DERIVATIVE, INSECTICIDAL/ACARICIDAL AGENT, AND PROCESS FOR PRODUCING THE SAME | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885ALDH1A1 1349/4885HPGD 816/4885 |
| US-20250339437-A1 | TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF | BTK, SYK, LCK | AR 4405/4885ALDH1A1 3490/4885HPGD 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.